To further explore treatment options, Li et al. conducted a single-arm, interventional, phase II clinical trial (NCT03923166) to examine the effectiveness and security of erlotinib combined with metronomic CBP in HER2+ metastatic BC [140]. Here, ERBB2 is linked to breast cancer.